Hereditary Spastic Paraparesis: Clinical Trials

2 trials for Hereditary Spastic Paraparesis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 not yet recruiting. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Not yet recruiting 1
Phase 11Not yet recruiting 1

Follow Hereditary Spastic Paraparesis: new trials by email Literature Review of Hereditary Spastic Paraparesis trials Research Report on Hereditary Spastic Paraparesis

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)
BFB-101 (AAV9-CBh-AP4B1) - HSP, Hereditary Spastic Paraplegia
Phase 1 / Phase 2Not yet recruitingBlackfinBio Ltd52025-08-012025-04-28
Testing Miglustat Administration in Subjects With Spastic Paraplegia 11
Miglustat 100 MG - Hereditary Spastic Paraparesis
Phase 2CompletedIRCCS Fondazione Stella Maris102021-06-152022-04-11

Narrower conditions

Spastic Paraplegia, Hereditary (2)  ·  Movement Disorders (1)  ·  Muscle Spasticity (1)

Broader conditions

Congenital Abnormalities (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Genetic Diseases, Inborn (2)  ·  Hereditary Sensory and Motor Neuropathy (2)  ·  Heredodegenerative Disorders, Nervous System (2)  ·  Nervous System Diseases (2)  ·  Nervous System Malformations (2)  ·  Neurodegenerative Diseases (2)  ·  Neuromuscular Diseases (2)  ·  Peripheral Nervous System Diseases (2)  ·  Polyneuropathies (2)  ·  Central Nervous System Diseases (1)  ·  Muscle Hypertonia (1)  ·  Muscular Diseases (1)  ·  Musculoskeletal Diseases (1)

Interventions

miglustat (1)

Sponsors

BlackfinBio Ltd (1)  ·  IRCCS Fondazione Stella Maris (1)

Countries

Italy (1)  ·  United States (1)

Top investigators

Filippo M Santorelli, MD PhD (1)

Results publications

PMID 41491634

NIH funding

2019 (1)